Valuation: Talphera, Inc.

Market Cap 58.65M 52.11M 48.64M 44.33M 83.61M 5.64B 84.39M 589M 228M 2.88B 220M 215M 9.25B P/E 2026 *
-5.22x
P/E 2027 * -5.2x
Enterprise Value 58.65M 52.11M 48.64M 44.33M 83.61M 5.64B 84.39M 589M 228M 2.88B 220M 215M 9.25B EV / Sales 2026 *
-
EV / Sales 2027 * 131x
Free-Float
78.59%
Yield 2026 *
-
Yield 2027 * -
1 day+0.89%
1 week-4.24%
Current month-2.59%
1 month-5.83%
3 months+5.61%
6 months+56.44%
Current year-0.88%
1 week 1.09
Extreme 1.09
1.21
1 month 1.09
Extreme 1.09
1.26
Current year 0.69
Extreme 0.6866
1.5
1 year 0.69
Extreme 0.6866
1.57
3 years 0.38
Extreme 0.38
1.61
5 years 0.38
Extreme 0.38
21
10 years 0.38
Extreme 0.38
115
Manager TitleAgeSince
Chief Executive Officer 58 05/03/2017
Director of Finance/CFO 56 31/07/2017
Chief Tech/Sci/R&D Officer - 30/09/2024
Director TitleAgeSince
Director/Board Member 60 31/07/2006
Director/Board Member 72 31/01/2010
Chairman 75 10/02/2013
Date Insider Type Main position Quantity % Market Cap. Importance
20/05/26 Tax

Chief Technology Officer

-4,518 0.0090%
02/04/26 Tax

Chief Executive Officer

9,938 0.0199%
02/04/26 Tax

Chief Technology Officer

2,444 0.0049%
Change 5-day change 1-year change 3-year change Capi.($)
+0.89%-4.24%+20.06%+105.45% 58.65M
-0.61%-3.43%+39.40%+112.31% 1,019B
-1.02%-5.60%+37.67%+65.02% 617B
+1.11%-0.58%+11.10%+77.28% 464B
+0.34%-3.01%+61.21%+40.71% 356B
-0.95%-4.05%+21.60%+39.37% 333B
-1.46%-2.89%+11.84%+24.60% 267B
-1.35%-5.43%-4.69%+8.40% 244B
-1.04%-2.79%+35.52%+51.34% 218B
-1.87%-4.10%+30.92%+95.33% 179B
Average -0.12%-3.48%+26.46%+61.98% 369.72B
Weighted average by Cap. +0.42%-3.33%+30.52%+68.96%

Financials

2026 *2027 *
Net sales - 447K 397K 371K 338K 637K 42.97M 643K 4.49M 1.74M 21.97M 1.68M 1.64M 70.5M
Net income -15.61M -13.87M -12.94M -11.8M -22.25M -1.5B -22.46M -157M -60.7M -767M -58.6M -57.33M -2.46B -18.63M -16.56M -15.45M -14.08M -26.56M -1.79B -26.81M -187M -72.46M -916M -69.96M -68.44M -2.94B
Net Debt - -
Logo Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Employees
12
Date Price Change Volume
02/10/26 US$1.130 +0.89% 345,050
01/10/26 US$1.120 -3.45% 106,401
30/09/26 US$1.160 -0.85% 56,100
29/09/26 US$1.170 -1.68% 66,897
28/09/26 US$1.190 +0.85% 188,292
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.130USD
Average target price
3.125USD
Spread / Average Target
+176.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TLPH Stock